Indication

COVID-19 Induced Pulmonary Fibrosis

1 clinical trial

1 product

Clinical trial

"Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis"

Status: Recruiting, Estimated PCD: 2023-10-11

Product